Cidara Price To Sales Ratio from 2010 to 2024
| CDTX Stock | USD 20.40 2.95 16.91% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 1.08625884 | Current Value 1.03 | Quarterly Volatility 2.11600368 |
Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14 M or Other Operating Expenses of 63.2 M, as well as many indicators such as Price To Sales Ratio of 1.03, Dividend Yield of 0.0 or Days Sales Outstanding of 111. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
Cidara | Price To Sales Ratio |
Latest Cidara Therapeutics' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Cidara Therapeutics over the last few years. Price to Sales Ratio is figured by comparing Cidara Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cidara Therapeutics sales, a figure that is much harder to manipulate than other Cidara Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Cidara Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 2.28 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Cidara Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 4.41 | |
| Geometric Mean | 3.59 | |
| Coefficient Of Variation | 48.00 | |
| Mean Deviation | 1.78 | |
| Median | 5.50 | |
| Standard Deviation | 2.12 | |
| Sample Variance | 4.48 | |
| Range | 6.0657 | |
| R-Value | (0.71) | |
| Mean Square Error | 2.42 | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (0.33) | |
| Total Sum of Squares | 62.68 |
Cidara Price To Sales Ratio History
About Cidara Therapeutics Financial Statements
Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 1.09 | 1.03 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.